Biologically Active Small Molecules

Bezafibrate is a well established pan-PPAR activator. This fibrate drug has over 25 years of therapeutic use with a good safety profile.

A selective inhibitor of HDAC3 (IC₅₀ = 289 nM) that alone or in combination with bortezomib has been shown to dose-dependently inhibit tumor growth in a mouse model of multiple myeloma.

A selective inhibitor of HDAC3 (IC₅₀ = 289 nM) that alone or in combination with bortezomib has been shown to dose-dependently inhibit tumor growth in a mouse model of multiple myeloma.

A selective inhibitor of HDAC3 (IC₅₀ = 289 nM) that alone or in combination with bortezomib has been shown to dose-dependently inhibit tumor growth in a mouse model of multiple myeloma.

A selective inhibitor of HDAC3 (IC₅₀ = 289 nM) that alone or in combination with bortezomib has been shown to dose-dependently inhibit tumor growth in a mouse model of multiple myeloma.

A pan FGFR inhibitor (IC₅₀s = 0.9, 1.

A pan FGFR inhibitor (IC₅₀s = 0.9, 1.

A pan FGFR inhibitor (IC₅₀s = 0.9, 1.

A pan FGFR inhibitor (IC₅₀s = 0.9, 1.

A PARP inhibitor and insulin sensitizer blocks self-ADP-ribosylation of nuclear PARP (Ki = 57 &microM) and mono-ADP-ribosylation of GRP78 acts as a co-inducer of Hsp72, augmenting expression induced by Hsf1 in adipocytes and skeletal muscles and

A PARP inhibitor and insulin sensitizer blocks self-ADP-ribosylation of nuclear PARP (Ki = 57 &microM) and mono-ADP-ribosylation of GRP78 acts as a co-inducer of Hsp72, augmenting expression induced by Hsf1 in adipocytes and skeletal muscles and

A PARP inhibitor and insulin sensitizer blocks self-ADP-ribosylation of nuclear PARP (Ki = 57 &microM) and mono-ADP-ribosylation of GRP78 acts as a co-inducer of Hsp72, augmenting expression induced by Hsf1 in adipocytes and skeletal muscles and